Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Daniele Spalletta
Observed name:
D Spalletta
Institution:
University of Rome Tor Vergata
Observed institution:
University of Rome Tor Vergata
ORCID:
0009-0009-4932-5344
Observed ORCID:
0009-0009-4932-5344
OpenAlex ID:
A5100284354
Role of low-frequency integrase strand transfer inhibitor resistance mutations on virological outcomes in antiretroviral therapy-naïve individuals initiating second-generation integrase inhibitors
2025
·
Daniele Armenia
, Greta Marchegiani
, et al.
·
Journal of Global Antimicrobial Resistance
·
7
Development of a Next‐Generation Sequencing Protocol for Assessing Lenacapavir Resistance in HIV‐1 Capsid
2025
·
Omar El Khalili
, Collins Ambe Chenwi
, et al.
·
Journal of Medical Virology
·
1
PDF
Virological outcomes, resistance profile and viral evolution of lenacapavir-based regimens in heavily treatment-experienced people: data from the PRESTIGIO Registry
2026
·
Maria Mercedes Santoro
, Daniele Spalletta
, et al.
·
Journal of Antimicrobial Chemotherapy
PDF
Real-world evaluation of HIV-1 reservoir and resistance in virologically suppressed people after 52 weeks of treatment with long-acting cabotegravir + rilpivirine
2026
·
Greta Marchegiani
, Francesco Paolo Antonucci
, et al.
·
International Journal of Antimicrobial Agents
OC23 Evaluation of the viral reservoir in virologically suppressed people with HIV treated with LA cabotegravir + rilpivirine regimen
2025
·
G Marchegiani
, F Antonucci
, et al.
·
Sexually Transmitted Infections
OC22 Evaluation of genetic variability and resistance profile in highly treatment-experienced people with HIV-1 with multi-drug resistance enrolled in the PRESTIGIO registry treated with lenacapavir
2025
·
MM Santoro
, D Spalletta
, et al.
·
Sexually Transmitted Infections
Air Pollution and post-acute sequelae of Covid-19: a multicentric study based on the EuCARE Project
2024
·
André Almeida
, Alessandro Cozzi-Lepri
, et al.
·
European Respiratory Journal
P-224 Depth coverage and HIV-1 variability negatively affect the performance of the ‘HIV-1 solution v2’ NGS sequencing kit for drug resistance monitoring
2024
·
F Saladini
, G Marchegiani
, et al.
·
Sexually Transmitted Infections
PDF
OC-16 Do low-frequency drug-resistant HIV-1 variants have a role on first-line INSTI-containing regimens? A case-control study from the ICONA cohort
2024
·
D Armenia
, G Marchegiani
, et al.
·
Sexually Transmitted Infections
PDF
Show more works
View as search
Works count:
9
Citation count:
8
H-index:
1
I10-index:
Year
Topic
Type